Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Docetaxel is named as an intervention in 183 current clinical trials in our China, USA, UK, Ireland and India registers. 107 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Merck Sharp & Dohme LLC (11). The most-studied condition is Breast Cancer. The EU clinical trials register (CTIS) separately lists 5 authorised or ongoing trials, 1 with a site in Ireland.

Trials by status

Recruiting10758%
Not yet open179%
Active, closed5832%
By invitation11%

Trials by phase

Phase 37742%
Phase 25530%
Phase 1/2179%
Phase 1179%
Phase 2/395%
Not applicable42%
Observational21%
Phase 421%

Clinical trials of Docetaxel

183 trials

Study	Phase	Status	Lead sponsor	Registers
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer NCT04136782 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Recruiting	Shengjing Hospital	China
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer NCT04547907 · ClinicalTrials.gov ↗ · Breast Cancer,HER2-positive	Phase 3	Recruiting	Henan Cancer Hospital	China
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT04928846 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Recruiting	AbbVie	UK, USA, China
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer NCT05430399 · ClinicalTrials.gov ↗ · Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer NCT05754853 · ClinicalTrials.gov ↗ · Advanced or Metastatic Urothelium Cancer	Phase 3	Recruiting	Shanghai Miracogen Inc.	China
Study of Comparing of With and Without Sequential Therapy of S-1 NCT05813015 · ClinicalTrials.gov ↗ · Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect	Phase 3	Recruiting	Zhejiang University	China
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC NCT05983783 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect	Phase 3	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects NCT06079983 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC NCT06102395 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab	Phase 3	Recruiting	Beijing Tongren Hospital	China
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer NCT06194734 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Beijing Konruns Pharmaceutical Co., Ltd.	China
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer NCT06296706 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	China
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer NCT06340568 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	BioNTech SE	UK, USA, China
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor NCT06472245 · ClinicalTrials.gov ↗ · Patients With Non-Small Cell Lung Cancer	Phase 3	Recruiting	OSE Immunotherapeutics	UK, USA
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) NCT06520345 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer	Phase 3	Recruiting	Telix Pharmaceuticals (Innovations) Pty Limited	UK, USA
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer NCT06545955 · ClinicalTrials.gov ↗ · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	Phase 3	Recruiting	Ferring Pharmaceuticals	USA
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) NCT06644781 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, China
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases NCT06699212 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Rakuten Medical, Inc.	USA, China
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma NCT06738251 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma	Phase 3	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In NCT06745908 · ClinicalTrials.gov ↗ · NSCLC Stage IV	Phase 3	Recruiting	ImmunityBio, Inc.	UK, USA
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) NCT06857175 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784 · NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC	Phase 3	Recruiting	Revolution Medicines, Inc.	Ireland, UK, USA
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737 · ClinicalTrials.gov ↗ · Prostate Cancer, Prostatic Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) NCT06952504 · Endometrial Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, China
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) NCT07144280 · ClinicalTrials.gov ↗ · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma	Phase 3	Recruiting	Pfizer	UK, USA, India, China
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer NCT07213674 · Metastatic Castration-resistant Prostate Cancer	Phase 3	Recruiting	Amgen	UK, USA
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer NCT07225946 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, Castration-Resistant	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. NCT07284134 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations NCT07291037 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer NCT07365995 · Metastatic Castration-resistant Prostate Cancer	Phase 3	Recruiting	BioNTech SE	UK, USA, China
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer NCT07366528 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer	Phase 3	Recruiting	Ruijin Hospital	China
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer NCT07377643 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.	China
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer NCT07416994 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	China
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) NCT07419295 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer NCT07441460 · ClinicalTrials.gov ↗ · Resectable HER2-positive Breast Cancer	Phase 3	Recruiting	Shanghai JMT-Bio Inc.	China
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy NCT07487896 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	China
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment NCT07518147 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer NCT07518173 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation NCT07566052 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	USA, China
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) NCT07660094 · ClinicalTrials.gov ↗ · Non-squamous, Non-Small Cell Lung Cancer	Phase 3	Recruiting	Candel Therapeutics, Inc.	USA
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation NCT07668752 · ClinicalTrials.gov ↗ · KRAS G12D Mutation, NSCLC (Non-small Cell Lung Cancer)	Phase 3	Recruiting	Genfleet Therapeutics (Shanghai) Inc.	China
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1) NCT07723248 · ClinicalTrials.gov ↗ · Metastatic Castration Resistant Prostate Cancer	Phase 3	Recruiting	ORIC Pharmaceuticals	USA
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3)	Phase 3	Recruiting	Shanghai Jiao Tong University School of Medicine	China
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer NCT04576143 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Neoadjuvant Chemotherapy	Phase 2/3	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy NCT05427383 · ClinicalTrials.gov ↗ · Stomach Cancer	Phase 2/3	Recruiting	Shanghai JMT-Bio Inc.	China
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer NCT07459751 · ClinicalTrials.gov ↗ · Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	Shanghai Henlius Biotech	China
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction NCT04840264 · ClinicalTrials.gov ↗ · Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis	Phase 2	Recruiting	Sixth Affiliated Hospital, Sun Yat-sen University	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer NCT05638594 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC NCT05918328 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-positive Breast Cancer	Phase 2	Recruiting	Henan Cancer Hospital	China
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer NCT05999994 · ClinicalTrials.gov ↗ · Neoplasms, Child, Adolescent	Phase 2	Recruiting	Eli Lilly and Company	UK, USA
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） NCT06107673 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Hebei Medical University Fourth Hospital	China
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer NCT06141226 · ClinicalTrials.gov ↗ · Non-small-cell Lung Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing NCT06145308 · ClinicalTrials.gov ↗ · Salivary Gland Carcinoma, Precision Therapy	Phase 2	Recruiting	Peking Union Medical College	China
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study NCT06254690 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) NCT06387056 · ClinicalTrials.gov ↗ · Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy. NCT06421298 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Jinghui Wang	China
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer NCT06463665 · ClinicalTrials.gov ↗ · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer	Phase 2	Recruiting	Genelux Corporation	USA
An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting NCT06749886 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) NCT06780098 · ClinicalTrials.gov ↗ · Lung Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] NCT06783647 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment NCT06841055 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	BioNTech SE	UK, USA
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy NCT06924606 · ClinicalTrials.gov ↗ · Advanced NSCLC	Phase 2	Recruiting	Shanghai Junshi Bioscience Co., Ltd.	China
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC NCT06927180 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3)	Phase 2	Recruiting	Henan Cancer Hospital	China
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Myelosuppression	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors NCT06947291 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors	Phase 2	Recruiting	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	China
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) NCT06951646 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)	Phase 2	Recruiting	Second Xiangya Hospital of Central South University	China
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer NCT07102381 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Breast Cancer	Phase 2	Recruiting	Jazz Pharmaceuticals	USA
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC NCT07246863 · ClinicalTrials.gov ↗ · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor	Phase 2	Recruiting	CatalYm GmbH	USA
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer NCT07287150 · Metastatic Castration-Resistant Prostate Cancer	Phase 2	Recruiting	Hoffmann-La Roche	UK, USA
WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC NCT07330050 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
ctDNA in HER2+ EBC Neoadjuvant Treatment NCT07335081 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 · Solid Tumors	Phase 2	Recruiting	Mirati Therapeutics Inc.	UK, USA, China
Evaluation of the Efficacy and Safety of Darolutamide + ADT Combined With Low-dose Docetaxel in mHSPC NCT07503379 · ClinicalTrials.gov ↗ · mHSPC	Phase 2	Recruiting	Yonghong Li	China
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure NCT07528274 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07601737 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer	Phase 2	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors NCT07669415 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 2	Recruiting	LaNova Medicines Limited	China
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors NCT04895709 · ClinicalTrials.gov ↗ · Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer	Phase 1/2	Recruiting	Bristol-Myers Squibb	USA
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) NCT05431270 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Phanes Therapeutics	USA
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. NCT05867420 · Advanced Solid Tumors	Phase 1/2	Recruiting	AskGene Pharma, Inc.	USA, China
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult	Phase 1/2	Recruiting	Krystal Biotech, Inc.	USA
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, Castration-Resistant	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer NCT06568094 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours NCT06682780 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	LaNova Medicines Limited	China
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer NCT06732531 · ClinicalTrials.gov ↗ · Bladder Cancer, Non Muscle Invasive	Phase 1/2	Recruiting	Zhuhai Beihai Biotech Co., Ltd	China
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272 · ClinicalTrials.gov ↗ · Castration-Resistant Prostatic Cancer, Metastasis	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA
AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma	Phase 1/2	Recruiting	Akeso	China
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) NCT07070440 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 1/2	Recruiting	Dizal Pharmaceuticals	China
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer NCT07590934 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer	Phase 1/2	Recruiting	AstraZeneca	UK, USA
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer NCT02889666 · ClinicalTrials.gov ↗ · Recurrent Non-small Cell Lung Cancer	Phase 1	Recruiting	Shanghai Jiao Tong University School of Medicine	China
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 1	Recruiting	Memgen, Inc.	USA
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer NCT05142189 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 1	Recruiting	BioNTech SE	UK, USA
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)	Phase 1	Recruiting	Exelixis	UK, USA
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China
A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer NCT05818683 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer	Phase 1	Recruiting	Janssen Research & Development, LLC	USA
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT05942001 · ClinicalTrials.gov ↗ · Advanced Prostate Cancer	Phase 1	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors NCT05954312 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	Vividion Therapeutics, Inc.	USA
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors NCT06241456 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Fate Therapeutics	USA
A Study of KK2269 in Adult Participants With Solid Tumors NCT06266299 · Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma	Phase 1	Recruiting	Kyowa Kirin Co., Ltd.	USA
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC NCT06868732 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer	Phase 1	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer NCT07381829 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1	Recruiting	HC Biopharma Inc.	China
Adjuvant Chemotherapy for High Malignant Prostate Cancer NCT06864533 · ClinicalTrials.gov ↗ · Prostate Cancer, Radiation Therapy, Chemotherapy	Observational	Recruiting	Peking University First Hospital	China
The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma NCT05494190 · ClinicalTrials.gov ↗ · Hypopharyngeal Carcinoma	Not applicable	Recruiting	Eye & ENT Hospital of Fudan University	China
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer NCT05800054 · ClinicalTrials.gov ↗ · Esophageal Neoplasms, Adverse Drug Event	Not applicable	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer NCT06234137 · ClinicalTrials.gov ↗ · Breast Neoplasm Female	Not applicable	Recruiting	Wang Ouchen	China
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer NCT07093931 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 4	Not yet open	Shandong Cancer Hospital and Institute	China
Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC NCT07242274 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)	Phase 3	Not yet open	Jemincare	China
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma NCT07768189 · ClinicalTrials.gov ↗ · Oropharyngeal Carcinoma (OPC)	Phase 3	Not yet open	Corbus Pharmaceuticals Inc.	UK, USA
A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT07795346 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Not yet open	Antengene Biologics Limited	China
JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer NCT07797153 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 3	Not yet open	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy NCT07831863 · ClinicalTrials.gov ↗ · Lung Squamous Cell Carcinoma	Phase 3	Not yet open	Mabwell (Shanghai) Bioscience Co., Ltd.	China
Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy NCT07718737 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2/3	Not yet open	Multitude Therapeutics Inc.	USA
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC NCT06684158 · ClinicalTrials.gov ↗ · GC/GEJC	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer NCT06713057 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer	Phase 2	Not yet open	West China Hospital	China
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. NCT07136974 · ClinicalTrials.gov ↗ · Breast Cancer, HER2 + Breast Cancer	Phase 2	Not yet open	Henan Cancer Hospital	China
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer NCT07246317 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer NCT07268794 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	Phase 2	Not yet open	Fudan University	China
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing） NCT07609251 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Not yet open	Sinocelltech Ltd.	China
A Single-Arm Study of QL1706 Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric/GEJ Adenocarcinoma NCT07828873 · ClinicalTrials.gov ↗ · Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	The First Affiliated Hospital of Zhengzhou University	China
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. NCT06136988 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Esophageal Squamous Carcinoma	Phase 1/2	Not yet open	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	China
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion NCT07699757 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors	Phase 1	Not yet open	Haisco Pharmaceutical Group Co., Ltd.	China
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study NCT05287308 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Not yet open	Chinese Academy of Medical Sciences	China
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression NCT07618624 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer	Phase 2	By invitation	Sun Yat-sen University	China
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC NCT01933932 · Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV	Phase 3	Active, closed	AstraZeneca	UK, USA
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer NCT01957436 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer	Phase 3	Active, closed	UNICANCER	Ireland
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] NCT02486718 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations NCT03390504 · ClinicalTrials.gov ↗ · Urothelial Cancer	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer NCT04025879 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer NCT04193059 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Fudan University	China
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) NCT04634877 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) NCT04656652 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation NCT04685135 · ClinicalTrials.gov ↗ · Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer	Phase 3	Active, closed	Mirati Therapeutics Inc.	Ireland, UK, USA, China
Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline NCT04723875 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms, Cervical Cancer	Phase 3	Active, closed	Huazhong University of Science and Technology	China
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT05089734 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). NCT05116189 · Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer NCT05132075 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Novartis Pharmaceuticals	USA, India, China
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) NCT05173987 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) NCT05296798 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, India, China
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT05348577 · ClinicalTrials.gov ↗ · Prostate Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy NCT05450692 · Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	Ireland, UK, USA, India, China
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors NCT05671510 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Active, closed	OncoC4, Inc.	UK, USA, China
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer NCT06012435 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) NCT06074588 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) NCT06118333 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd.	China
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 NCT06346392 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) NCT06356311 · ClinicalTrials.gov ↗ · Gastroesophageal Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). NCT06551324 · ClinicalTrials.gov ↗ · Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Phase 3	Active, closed	Pfizer	UK, USA, China
A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301) NCT06629597 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 3	Active, closed	MediLink Therapeutics (Suzhou) Co., Ltd.	China
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) NCT06635824 · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC	Phase 3	Active, closed	Genmab	Ireland, UK, USA
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer NCT06747338 · ClinicalTrials.gov ↗ · Early or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Shanghai JMT-Bio Inc.	China
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer NCT06764485 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer	Phase 3	Active, closed	Celgene	Ireland, UK, USA, China
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure NCT06935409 · ClinicalTrials.gov ↗ · Osteosarcoma	Phase 3	Active, closed	Hansoh BioMedical R&D Company	China
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer NCT07196774 · ClinicalTrials.gov ↗ · Early-stage or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature NCT02641847 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, Breast Cancer	Phase 2/3	Active, closed	Fudan University	China
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) NCT03178552 · Non-Small Cell Lung Cancer	Phase 2/3	Active, closed	Hoffmann-La Roche	USA, China
Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric Adenocarcinoma NCT03691454 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma	Phase 2/3	Active, closed	Peking University	China
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy NCT04655976 · Lung Cancer, Non-Small Cell	Phase 2/3	Active, closed	GlaxoSmithKline	UK, USA
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients NCT05426486 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2/3	Active, closed	Caigang Liu	China
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612 · ClinicalTrials.gov ↗ · Neoplasm Metastasis	Phase 2	Active, closed	Genentech, Inc.	UK, USA, China
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors NCT03228667 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma	Phase 2	Active, closed	ImmunityBio, Inc.	USA
Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer NCT03456843 · ClinicalTrials.gov ↗ · Stage IV Prostate Adenocarcinoma AJCC v7	Phase 2	Active, closed	Yale University	China
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer NCT03505320 · ClinicalTrials.gov ↗ · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer	Phase 2	Active, closed	Astellas Pharma Global Development, Inc.	USA
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC NCT04172259 · Breast Cancer, Neoadjuvant Chemotherapy	Phase 2	Active, closed	Sun Yat-sen University	China
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC NCT04736823 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Akeso	China
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer NCT04872985 · ClinicalTrials.gov ↗ · Breast Cancer, Hormone-receptor Positive Breast Cancer	Phase 2	Active, closed	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. NCT05020457 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC NCT05054439 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd.	China
Study of Novel Treatment Combinations in Patients With Lung Cancer NCT05633667 · ClinicalTrials.gov ↗ · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
Study With Various Immunotherapy Treatments in Participants With Lung Cancer NCT05676931 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer NCT06445400 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd.	China
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) NCT06618014 · ClinicalTrials.gov ↗ · Breast Cancer, Triple Negative Breast Cancer	Phase 2	Active, closed	Sun Yat-sen University	China
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) NCT06632951 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 2	Active, closed	AbbVie	USA
A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma NCT07257575 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III	Phase 2	Active, closed	Guangdong Provincial People's Hospital	China
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction NCT07776639 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma	Phase 2	Active, closed	Yongxu Jia	China
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC NCT04140526 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma	Phase 1/2	Active, closed	OncoC4, Inc.	USA
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) NCT05094336 · ClinicalTrials.gov ↗ · Advanced MTAP-null Solid Tumors	Phase 1/2	Active, closed	Amgen	UK, USA, China
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer NCT05904379 · ClinicalTrials.gov ↗ · Advanced Non-small-cell Lung Cancer	Phase 1/2	Active, closed	Akeso	China
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) NCT02817633 · Neoplasms	Phase 1	Active, closed	Tesaro, Inc.	USA
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors NCT04721015 · ClinicalTrials.gov ↗ · Advanced Solid Tumors Cancer, Non Small Cell Lung Cancer (NSCLC)	Phase 1	Active, closed	AbbVie	USA
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies NCT06120075 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1	Active, closed	Arcus Biosciences, Inc.	USA
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice NCT07344779 · ClinicalTrials.gov ↗ · Metastatic Hormone-Sensitive Prostate Cancer	Observational	Active, closed	Bayer	UK

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Docetaxel in the EU trials register (CTIS)

5 trials · 1 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Docetaxel. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
OPTIMA YOUNG : Optimal Personalized Treatment of early breast cancer using Multi-parameter Analysis : focus on YOUNGer women 2024-519655-28-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Unicancer	Ireland + 6 more
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP) 2025-523055-55-00 · Neoplasms	Phase 2	Authorised	Universitaetsklinikum Heidelberg AöR	Germany
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer 2025-524445-27-00 · Male Urogenital Diseases	Phase 3	Authorised	BioNTech SE	Belgium, Spain, Italy + 3 more
A Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs 2025-522723-98-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Krystal Biotech Inc	France, Spain
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer 2025-523204-68-00 · CTIS ↗ · Neoplasms	Phase 2	Ongoing	Jazz Pharmaceuticals Ireland Limited	Italy, Spain, Germany

Docetaxel across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

12 single-substance products containing Docetaxel on the HPRA medicines list.

Docetaxel 20 mg/ml concentrate for solution for infusionSeacross Pharma (Europe) Limited · PA22766/001/001 · Marketed
DOCETAXEL KABI 120 mg/6 ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · EU/1/12/770/002
DOCETAXEL KABI 160 mg/8 ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · EU/1/12/770/003
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · EU/1/12/770/004
DOCETAXEL KABI 80 mg/4 ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · EU/1/12/770/001

All 12 Irish products →

Supply shortages

TaxotereEU (EMA) · Shortage resolved · first published 19 May 2016
Docetaxel InjectionUS (FDA) · Resolved · updated 20 Feb 2026

EU shortages US shortages German shortages

Conditions studied with Docetaxel

174 conditions

Breast Cancer18 Non-Small Cell Lung Cancer10 Non Small Cell Lung Cancer8 Advanced Solid Tumors6 HER2-positive Breast Cancer6 NSCLC (Non-small Cell Lung Cancer)5 Advanced Solid Tumor5 Metastatic Castration-resistant Prostate Cancer4 Prostate Cancer4 Metastatic Prostate Cancer4 Gastric Cancer4 Head and Neck Squamous Cell Carcinoma4

All 174 conditions

Condition (as registered)	Trials
Breast Cancer	18
Non-Small Cell Lung Cancer	10
Non Small Cell Lung Cancer	8
Advanced Solid Tumors	6
HER2-positive Breast Cancer	6
NSCLC (Non-small Cell Lung Cancer)	5
Advanced Solid Tumor	5
Metastatic Castration-resistant Prostate Cancer	4
Prostate Cancer	4
Metastatic Prostate Cancer	4
Gastric Cancer	4
Head and Neck Squamous Cell Carcinoma	4
Endometrial Cancer	3
Lung Cancer	3
Non-small Cell Lung Cancer (NSCLC)	3
Solid Tumor	3
Gastric Adenocarcinoma	3
Gastroesophageal Junction Adenocarcinoma	3
Advanced Cancer	3
Urothelial Carcinoma	3
NSCLC (Advanced Non-small Cell Lung Cancer)	3
NSCLC	2
Endometrial Neoplasms	2
Carcinoma, Non-Small-Cell Lung	2
Prostatic Neoplasms, Castration-Resistant	2
Esophageal Squamous Cell Carcinoma	2
Non-small Cell Lung Cancer	2
Locally Advanced or Metastatic Breast Cancer	2
Neoplasms	2
Bladder Cancer	2
Recurrent Head and Neck Squamous Cell Carcinoma	2
Cervical Cancer	2
Neoadjuvant Chemotherapy	2
Breast Cancer Early Stage Breast Cancer (Stage 1-3)	2
Neoadjuvant Therapy	2
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	2
Head and Neck Squamous Cell Carcinoma (HNSCC)	2
Triple Negative Breast Cancer	2
Chemotherapy Effect	2
Nasopharyngeal Carcinoma	2
NSCLC (Non-small Cell Lung Carcinoma)	1
Advanced or Metastatic Non-Small Cell Lung Cancer	1
Ovarian Cancer	1
Carcinoma, Ovarian Epithelial	1
Fallopian Tube Neoplasms	1
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC	1
Prostatic Neoplasms	1
Castration-Resistant Prostatic Cancer	1
Metastasis	1
Metastatic Non Small Cell Lung Cancer	1
Advanced Non Small Cell Lung Cancer	1
Lung Cancer, Non-Small Cell	1
Metastatic Castration-Resistant Prostate Cancer	1
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV	1
Solid Tumors	1
Advanced Non-Small Cell Lung Cancer	1
NSCLC Stage IV	1
Patients With Non-Small Cell Lung Cancer	1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)	1
Advanced or Metastatic Non-Small-Cell Lung Cancer	1
Resectable Non-Small-Cell Lung Cancer	1
Advanced MTAP-null Solid Tumors	1
Non-small Cell Carcinoma	1
Non-Small Cell Lung Cancer Metastatic	1
Non-Small Cell Lung Carcinoma	1
Metastatic Hormone-Sensitive Prostate Cancer	1
Neoplasm Metastasis	1
Urothelial Cancer	1
Gastroesophageal Junction Cancer	1
Gastroesophageal Cancer	1
Child	1
Adolescent	1
Oropharyngeal Carcinoma (OPC)	1
Renal Cell Carcinoma (RCC)	1
Metastatic Castration-Resistant Prostate Cancer (mCRPC)	1
Urothelial Carcinoma (UC)	1
Metastatic Solid Tumor	1
Lung Cancer, Non-small Cell	1
Lung Cancer Metastatic	1
Solid Tumor, Adult	1
Metastatic Castration-resistant Prostate Neoplasms	1
Metastatic Hormone-sensitive Prostate Cancer	1
Small Cell Lung Cancer	1
Advanced Non-squamous Non-small-cell Lung Cancer	1
Advanced Squamous Non-Small Cell Lung Carcinoma	1
Metastatic Non-squamous Non Small Cell Lung Cancer	1
Metastatic Squamous Non-Small Cell Lung Carcinoma	1
Non-squamous, Non-Small Cell Lung Cancer	1
Pharmacokinetics of Zolbetuximab	1
Gastro-esophageal Junction (GEJ) Cancer	1
Pharmacokinetics of Oxaliplatin	1
Gastric/Gastroesophageal Junction Adenocarcinoma	1
Microsatellite Stable Colorectal Cancer	1
Non-Small-Cell Lung Cancer	1
Metastatic Cancer	1
Pancreatic Ductal Adenocarcinoma	1
Lung Neoplasm	1
Metastatic Non-Squamous Non-Small Cell Lung Cancer	1
Adult Solid Tumor	1
Advanced Solid Tumors Cancer	1
Non Small Cell Lung Cancer (NSCLC)	1
Metastatic Castration Resistant Prostate Cancer	1
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	1
Metastatic Melanoma	1
Metastatic Head and Neck Carcinoma	1
Advanced Solid Tumor Cancer	1
Gastric Cancer Stage III	1
Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors	1
Recurrent or Metastatic Cervical Cancer	1
Advanced Non-small-cell Lung Cancer	1
Pancreatic Ductal Adenocarcinoma (mPDAC)	1
Advanced Esophageal Squamous Cell Carcinoma	1
Advanced Non-small Cell Lung Cancer	1
Pembrolizumab	1
Prostate Cancer (Adenocarcinoma)	1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	1
Stomach Cancer	1
Advanced or Metastatic Urothelium Cancer	1
KRAS G12D Mutation	1
Radiation Therapy	1
Chemotherapy	1
Gleason Score	1
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer	1
Salivary Gland Carcinoma	1
Precision Therapy	1
Locally Advanced Unresectable Esophageal Squamous Carcinoma	1
Head and Neck Cancer	1
Locally Advanced Thyroid Gland Carcinoma	1
Thyroid Cancer	1
Advanced Urothelial Carcinoma	1
Resectable HER2-positive Breast Cancer	1
Osteosarcoma	1
Head & Neck Cancer	1
HER2-negative Breast Cancer	1
Hypopharyngeal Carcinoma	1
Recurrent Non-small Cell Lung Cancer	1
Breast Neoplasm Female	1
Locally Advanced Prostate Cancer	1
Oligometastatic Prostate Cancer	1
Early or Locally Advanced HER2-positive Breast Cancer	1
Immune Checkpoint Inhibitors (ICIs)	1
Esophageal Neoplasms	1
Adverse Drug Event	1
Uterine Cervical Neoplasms	1
Early-stage or Locally Advanced HER2-positive Breast Cancer	1
Non-small-cell Lung Cancer	1
Non-small Cell Lung Cancer Stage IIIB/IV	1
Colorectal Adenocarcinoma	1
Hormone Sensitive Prostate Cancer	1
Breast Neoplasms	1
Myelosuppression	1
Hormone-receptor Positive Breast Cancer	1
Breast Cancer,HER2-positive	1
Advanced NSCLC	1
mHSPC	1
HER2 + Breast Cancer	1
Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	1
Gastric Cancer (GC)	1
Adjuvant Chemotherapy	1
Stage 3 Cancer	1
Docetaxel	1
GC/GEJC	1
Advanced Solid Tumour	1
Non Muscle Invasive	1
Lung Squamous Cell Carcinoma	1
Stage IV Prostate Adenocarcinoma AJCC v7	1
Advanced Prostate Cancer	1
Metastatic Gastric Adenocarcinoma	1
Metastatic Gastroesophageal Junction Adenocarcinoma	1
Peritoneal Carcinomatosis	1
Locally Advanced Gastric Adenocarcinoma	1
Breast Neoplasm	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1

By country register

Register	Trials	Recruiting
Clinical trials in China	139	80
Clinical trials in USA	83	46
Clinical trials in UK	53	25
Clinical trials in Ireland	13	5
Clinical trials in India	7	2
EU register (CTIS)	5	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Docetaxel trials

How many clinical trials are testing Docetaxel?

183 current trials in our China, USA, UK, Ireland and India registers name Docetaxel (also registered as HB1801) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Docetaxel trials recruiting patients?

Yes. 107 of the 183 trials are recruiting: 80 with sites in China, 46 with sites in USA, 25 with sites in UK, 5 with sites in Ireland and 2 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Docetaxel clinical trials?

Merck Sharp & Dohme LLC (11), AstraZeneca (7), Sichuan Baili Pharmaceutical Co., Ltd (7) and Hoffmann-La Roche (4), among 107 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Docetaxel clinical trials in Ireland?

Yes. 13 trials in our Ireland register (ClinicalTrials.gov), and 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Docetaxel licensed in Ireland?

Yes. The HPRA medicines list includes 12 single-substance products containing Docetaxel, for example Docetaxel 20 mg/ml concentrate for solution for infusion (Seacross Pharma (Europe) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Docetaxel shortage?

The registers we track list 2 entries for Docetaxel: Taxotere (EU: shortage resolved); US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Docetaxel works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Docetaxel works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Docetaxel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Docetaxel clinical trials